YouthBio Therapeutics has announced what it describes as significant preclinical results from a joint study with Dr Ocampo, demonstrating potential to slow or reverse age-related cognitive decline, according to the company.
The study tested partial reprogramming using Yamanaka factors OSK (Oct4, Sox2, Klf4) in aged mice. The company said that treated mice showed notable improvements in memory and learning functions compared to controls, suggesting that gene therapy–based partial reprogramming could help combat cognitive deterioration associated with aging.
YouthBio Therapeutics claims these findings strengthen its approach to developing gene therapies targeting cellular aging processes. By reprogramming cells to a more youthful state without fully resetting their identity, the company aims to avoid risks of tumor formation while harnessing regenerative benefits.
According to the company, the collaboration with Dr Ocampo combined YouthBio Therapeutics’ gene therapy platform with Dr Ocampo’s expertise in partial reprogramming to design and implement the study. The company said these results will guide further research into translating partial reprogramming from animal models to human applications.
YouthBio Therapeutics plans to advance its pipeline of gene therapies targeting age-related diseases, focusing on neurodegeneration and other conditions driven by cellular aging. The company claims its long-term goal is to move toward human clinical trials, subject to further validation and regulatory approvals.
The company believes these preclinical findings represent an important milestone in its mission to develop therapies that directly address biological aging as a root cause of cognitive decline.
